source
- Genentech pays Alector $100M for preclinical Parkinson’s prospectGenentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.
- Mimetic Medicines' peptide reduces pain-related sodium channels in mice, offering new neuropathic pain strategyResearchers at Mimetic Medicines tested a short lipidated peptide (SLiP) in mice and found it lowered the presence of Nav1.8 sodium channels on sensory neuron membranes. Reducing these channels hel…